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 CURRENTOPINION Hypothermic machine perfusion in liver
transplantation
Andrea Schlegel, Philipp Kron, and Philipp Dutkowski
Purpose of the review
The purpose of the review is to report recent human application of hypothermic machine liver perfusion,
and to discuss potential protective mechanisms.
Recent findings
Human application of hypothermic machine liver perfusion is still very limited. Currently, three transplant
centers apply this novel treatment in donation after cardiac death (DCD) or donation after brain death
(DBD) liver grafts. In all cases, endischemic perfusion was performed after initial cold storage for organ
transport. Perfusion conditions differ slightly in terms of oxygenation (pO2 15–60 kPa), perfusion route
(dual vs. portal), perfusion time (2–4h), and perfusate.
Summary
The current data support the hypothesis that applying endischemic hypothermic machine liver perfusion
protects extended criteria DBD and DCD livers from initial reperfusion injury, with better graft function and
less biliary complications. Hypothermic machine perfusion may therefore offer revitalization of liver grafts
before implantation by a simple and practical perfusion technique with a high impact on enlarging the
donor pool. Multicentric phase III randomized control trials in DBD and DCD liver transplantation have
been initiated to further test this strategy, which may establish machine liver perfusion in the clinical setting.
Keywords
danger-associated molecular patterns, mitochondria, oxygen, reactive oxygen species
INTRODUCTION
Organ perfusion at normothermic conditions has
been explored very early in the history of extracor-
poreal perfusion, compared with hypothermic per-
fusion [1]. However, the technical challenges of
providing sufficient oxygen without vascular dam-
age and infection prohibited any clinical appli-
cation in the first part of the last century. In
contrast, it has been recognized that lowering the
temperature during organ procurement was key to
induce low oxygen demand in cells, with consecu-
tive longer viability ex vivo [2]. Subsequently, cold
flush preservation and ice cooling permitted in the
1960s, the establishment of first clinical transplant
programs [3], and were also the conceptual basis for
cold perfusion in renal transplantation [4]. After
pioneering work, it became quickly clear that an
idealized perfusion circuit for extracorporeal organ
perfusion depends on four key components, for
example, pumping, sufficient supply of oxygen, a
filter system, and a reservoir [5–7]. It was also
reported already in the 1970s that high perfusion
flow at low temperatures increases the risk of
vascular endothelium injury by abnormal shear
stress [8]. Despite these important and still true
findings, hypothermic perfusion preservation
gradually lost favor in the following 2 decades for
several logistical and economic reasons. However, as
the continuous shortage of organs caused a world-
wide increase in the use of compromised donors, a
significant proportion of transplanted organs are
currently taken from extended criteria donors,
and also after circulatory death [donation after
cardiac death (DCD)] [9
&
]. These organs generally
suffer from a higher risk of dysfunction after implan-
tation, which trigger acute rejection and impaired
long-term graft survival [10,11]. Therefore, the
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concept of machine perfusion instead of conven-
tional static cold storage has been nowadays
revisited to improve graft viability [12]. The concur-
ring machine perfusion strategies for livers differ
in perfusate conditions, including particularly
temperature and timing of perfusion [13,14]. In this
review, we summarize recent developments in the
field of hypothermic machine liver perfusion, and
focus on clinical application in humans.
UPFRONT VS. ENDISCHEMIC PERFUSION
The key element of machine perfusion of organs is
to maintain viability and aerobic metabolism before
implantation. As any static cold storage leads to
anaerobic metabolism within short time, because
of the lack of oxygen and substrates [15], machine
perfusion has traditionally been designed as a con-
tinuous approach, starting directly after organ pro-
curement. In the past 10 years, it became, however,
clear that instead of continuous cold perfusion
upfront, endischemic perfusion after cold storage
is an attractive option [16–19]. Apart from
additional logistic advantages, endischemic per-
fusion implies also a lower risk of shear stress,
because of shorter perfusion time [20]. The idea
behind such endischemic machine perfusion after
initial cold storage relies on the assumption that
metabolic and structural changes during the ische-
mic period may not be irreversible. In fact, delivery
of oxygen under cold conditions turned out to be
very effective in uploading cellular energy with only
minor oxidative stress, in sharp contrast to exposure
of any ischemic tissue to oxygen at normothermic
conditions [21]. The underlying mechanism
involves predominantly a mitochondrial repair
[22,23]. Accordingly, short periods of hypothermic
oxygenated perfusion (HOPE) or hypothermic
oxygen persufflation increase ATP significantly in
several tissues within 1–2h [24,25
&
], and decrease
radical oxygen species (ROS) and danger-associated
molecular patterns (DAMPs) subsequently (High-
Mobility-Group-Box Protein 1, DNA fragments,
and histones) that release during implantation
[21,22,26]. Subsequently, several Toll-like receptors
2,4,9 and also receptor for advanced glycation end
products on membrane surfaces become less acti-
vated [26–28], and lead to less release of chemokines
(TNFa, CXCL2, and CXCL10) with less immune
response [21,23,27,29
&
,30,31].
Consistent to these experimental results,
hypothermic perfusion has recently been shown
to be also effective in human. Hypothermic dual
(portal vein and hepatic artery) perfusion of 20
standard DBD human livers was first reported in
2010 by Guarerra et al. [32]. Machine perfusion
was applied after previous cold storage and transport
of organs without additional oxygenation, but
reasonable oxygen availability in the perfusate
(pO2 15–20kPa). Machine-perfused livers showed
significantly less peak enzyme release and a shorter
hospital stay, as well as less early graft dysfunction
compared with a nonrandomized control group
[32]. In a further report from 2015, the same inves-
tigators showed less biliary complications after
application of hypothermic perfusion to marginal
DBD organs [33
&
]. Our group applied HOPE for
1–2h only through the portal vein in cold-stored
human DCD livers (Fig. 1a) [34]. A recent compari-
son of matched unperfused and HOPE perfused
extended DCD livers indicate significantly improved
graft survival because of less occurrence of intra-
hepatic biliary complications (Table 1) [35
&&
]. The
Groningen group applies HOPE through the portal
vein and the hepatic artery dual HOPE (DHOPE) in
extended DCD livers. The results confirm a greater
than 10-fold ATP increase by HOPE treatment and
less nonanastomotic biliary strictures in recipients
(Table 1) [36]. Randomized trials are initiated to
further evaluate the effect of hypothermic oxygen-
ated liver perfusion on DBD and DCD liver grafts
(hope-liver.com – Zurich, Groningen Institute for
Organ transplantation – GIOT).
DUAL VS. SINGLE PORTAL VEIN
PERFUSION
In the context of the abovementioned experiences
in human, there is a current debate whether cold
machine perfusion should be best performed by dual
perfusion through the hepatic artery and the portal
vein, or by single portal vein access. Importantly,
while dual perfusion under normothermic con-
ditions is essential for biliary function and epithelial
viability, hypothermic perfusion fundamentally
differs from physiological conditions.
First, during cold machine liver perfusion,
oxygen consumption of all liver cells, including
the extrahepatic bile duct is dramatically reduced
KEY POINTS
 Hypothermic machine liver perfusion is protective after
initial cold ischemia in human liver transplantation.
 The presence of oxygen in the perfusate is a key factor.
 The underlying mechanism is related to mitochondrial
repair and endothelial effects.
 Prediction of liver viability and further application in
steatotic livers are future-promising targets.
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[37]. Second, oxygen saturation is largely different
between hypothermic oxygenated perfusate (pO2
>80kPa) [13,34,35
&&
] and normothermic portal
pO2 in vivo (pO2<10kPa) [38]. Third, we show in
a recent study in pig and discarded human DCD
livers that single portal vein perfusion resulted in
complete graft supply (Fig. 1b), with simultaneous
perfusion of the entire extrahepatic choledochus by
small portal branches (Fig. 1c and d) [39]. This
finding correlates well with healthy bile duct epi-
thelia in the distal choledochus 2 weeks after trans-
plantation [40]. Single portal vein approach during
cold machine perfusion appears therefore as excel-
lent method delivering oxygen and substrates to the
entire biliary epithelia, which has been very recently
shown to be of utmost importance for regeneration
and protection against later cholangiopathy [30,41].
PERFUSATE ASPECTS
Human application of hypothermic liver perfusion
is currently done using Belzer’s machine perfusate
[34,35
&&
] or its modifications, including ketogluta-
rate, nitroglycerine, L-arginine, N-acetylcysteine,
and prostaglandin E1 (Vasosol) [32,33
&
]. No
conclusive comparison of machine liver perfusates
remains yet available. In principal, solutions with
low potassium and without starch appear advan-
tageous, as low potassium concentrations decrease
vascular resistance in the cold, whereas the presence
of starch increases viscosity [17]. Of note, perfusate
analysis during hypothermic machine liver per-
fusion allows prediction of subsequent peak liver
enzymes after transplantation [32]. No clear
thresholds, however, exist when to discard pumped
livers based on perfusate analysis.
OXYGEN
The delivery of oxygen under cold conditions to
different types of tissues has been tested long before
the development of hypothermic machine per-
fusion [42]. In this context, gaseous oxygen persuf-
flation was beneficial against warm and cold
ischemia in various organs and achieved better
organ quality compared with cold storage [43].
Based on these experiences on the key role of oxygen
and hypothermia, perfusates are actively oxygen-
ated (pO2 >80kPa) in two human applications of
hypothermic liver perfusion (Table 1), whereas in
Extended DCD liver graft during single portal
vein perfusion (HOPE)
Distal choledochus after single portal vein
perfusion (HOPE )
(a) (c)
(b) (d)
Portal vein
with cannula 
Hepatic artery
untouched
*
*
+
+
*: Lumen of ductus choledochus, +: choledochus wall with peribiliary glands.
Hemangioma
FIGURE 1. HOPE of human liver grafts: (a) HOPE through the portal vein of a human DCD liver (liver assist). (b) Fluorescence
under dark light confirmed complete liver perfusion within 10min during single portal vein HOPE (fluorescein in the perfusate).
(c) Hematoxylin and eosin staining of distal extrahepatic bile duct with healthy peribiliary glands (þ) after HOPE in DCD
livers. (d) Fluorescence under dark light confirmed the presence of fluorescein in the complete biliary duct wall (þ) after HOPE
through the portal vein alone. HOPE, hypothermic oxygenated perfusion.
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another series, surgeons rely on dissolved oxygen in
the perfusate (pO2 30kPa), which may be sufficient
at 4 8C for standard livers (Table 1) [32]. Previous
work, however, confirmed that hypothermic liver
perfusion with completely deoxygenated perfusate
failed to protect from reperfusion injury [22,29
&
]. Of
note, the rate of oxygen consumption during HOPE
is not stable but decreases rapidly during the first
hour, and ceases after 90min at a low baseline level
[13,22,34]. This effect relates to a decrease of elec-
tron-rich substrates during hypothermic oxygen-
ation [22]. HOPE may, therefore, provides a
reversible downregulation of mitochondrial chain
carriers, which leads to slow ‘switching on’ of mito-
chondrial electron transfer during normothermic
reperfusion [15,22].
MECHANISM
During ischemia, aerobic respiration is disabled by
the lack of oxygen and nutrients.
As a result, cellular energy reserves are depleted,
cytosolic ion concentrations are changed, and
cellular membranes become instable [44,45]. Liver
endothelial cells are particularly vulnerable to ische-
mia/reperfusion injury and develop serious altera-
tions during cold storage, such as retraction, cell
body detachment, and apoptosis, whereas hepato-
cytes appear to bemostly unaffected [46,47]. During
warm reperfusion, early sinusoidal endothelial cell
(SEC) necrosis is followed by delayed hepatocyte
apoptosis [47]. However, severe changes in SECs,
resulting in disappearance of the SEC lining do
not decrease the overall viability of rat livers after
transplantation, since they are similar under both
nonlethal and lethal conditions [47]. In contrast,
the main pathological event was shown to be the
profound alteration of hepatic microcirculation
with loss of the extracellular matrix and finally
interruption of sinusoidal flow leading to hepato-
cyte necrosis (Fig. 2) [47]. Hypothermic liver per-
fusion potentially addresses at least three different
protective mechanisms in parenchymal and non-
parenchymal cells against lethal impairment of hep-
atic flow (Fig. 3).
Endothelial cell effects
Flow cessation per se results in a significant
reduction of several endothelial vasoprotective
pathways leading to cell activation and apoptosis.
The negative effects of cold storage conditions are
partly because of the loss of expression of the vaso-
protective transcription factor Kruppel-like factor 2
(KLF2) [48]. Machine perfusion may trigger endo-
thelial protection because of upregulation of shear
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stress-sensitive protective genes (Fig. 3) [46]. Of
note, however, a recent study failed to prove alter-
ation of KLF2, in neither cold storage or machine
perfusion compared with controls in porcine DCD
kidneys, but showed increased activation of eNOS
[49]. Based on this, the impact of biomechanical
sinusoidal stimulation during machine perfusion
appears currently unclear, and needs further clarifi-
cation. Importantly, however, perfusion at high
pressures in the cold (>4mmHg) has been shown
to exert severe injury in livers [22]. This fact points
to the importance of endothelial effects during
hypothermic liver perfusion.
Hepatocyte effects
In parallel to endothelial damage, current research
indicates a key role of hepatocyte released DAMPs
ROS
DAMPs 
ROS
ROS ROS Neutrophil (APC)activation and migration 
TLR4
ROS
Cytokines
(e.g., IL-1β, IL-6,
TNF-α, IL-10,
IL-12, CLC2,
CXLC8, and10)  
Activated
Kupffer and
dendritic
cells
T-cell
activation
B-cell
signaling
II.
Kupffer cell activation
30 min – 6 h
I.
Initial ROS release
(mitochondrial injury)
0–30 min 
Hepatocyte Kupffer anddendritic cells
T cells
APC
Neutrophil +platelet
attachment to SEC
III.
General inflammation/ immune response
>6 h
APC
Cytokines
(e.g., IL-1β, IL-2
IFNγ, IL13, and IL-17)
CD40/
CD128
8-OHdG
TIM-1TIM-4
RAGE
ATP
depletion
DAMPs
signaling
Sinusoidal
endothelial cell (SEC)
ICAM/PCAM, eNOS, and KLF2
ROS
DAMPs
TLR9
FIGURE 2. Time frame and cascade of reperfusion injury as well as link to immune response. eNOS: endothelial nitric oxide
synthase.
Hypothermic
oxygenated
perfusion
(HOPE)
Initial warm and cold graft ischemia
Reperfusion (at 37°C)
Microcirculatory impairment
interruption of sinusoidal flow
necrosis
1. Cleaning of glycocalix
1. ATP/ADP
reloading
(all cell types)
DAMP (HMGB-1
signaling)
Chemokine / ROS
signaling
Initial mitochondrial
ROS release
(all cell types)
Endothelial activation
Kupffer cell activation
dendritic cell maturation
Metabolic
effect
Effect on
endothelium
2. Down-regulation
of electron transfer  
3. Removal of
accumulated
substrates 
2. Upregulation of shear stress
sensitive genes (KLF  and eNOS) 
Neutrophil and platelet adhesion
Cellular
defense
T-cell activation
complement activation
Activation of
protective
pathways
HIF1a, SIRT1,
Nrf2,PKC 
Protect
Protect
Protect
FIGURE 3. Potential protective mechanisms of hypothermic oxygenated perfusion. HIF: hypoxia-inducible factor; KC, Kupffer
cell; Nrf2: Nuclear factor (erythroid-derived 2)-like 2; PKCe: protein kinase C epsilon; SIRT1: SIRT-1: gene of NAD-dependent
deacetylase sirtuin-1.
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[26,27,44,50] during early reperfusion, with a steep
arise during the first 4–6h [26,27,51]. From this
point on, reperfusion injury shifts from pure meta-
bolic distress to a potentially lethal innate immune
response [27], involving several nonparenchymal
cells (SEC, antigen-presenting cells [Kupffer cells
and dendritic cells (KC and DC)], leukocytes (T cells
and neutrophils) and chemokines, as well as
additional ROS (Figs. 2 and 3). HOPE triggers a
unique decrease of DAMPs during early reperfusion
of DCD liver grafts, as shown in several transplant
models (Fig. 3) [16,21,22,29
&
,30].
Mitochondrial effects
Metabolic pathways are responsible for mitochon-
drial ROS production in a large range of tissues,
including livers, kidneys, hearts, and brain
[52–54]. Selective accumulation of the citric acid
cycle intermediate succinate has been shown
recently as a universal signature of ischemia, and
is responsible for mitochondrial ROS production in
all cell types during reperfusion [55
&&
]. Ischemic
succinate accumulation arises at least partly from
reversal of succinate dehydrogenase (complex II).
Upon reperfusion, the accumulated succinate is
rapidly reoxidized, driving extensive ROS gener-
ation by reverse electron transport at mitochondrial
complex I [55
&&
,56]. Decreased succinate load before
reperfusion is therefore sufficient to improve I/R
injury [55
&&
]. These findings are particularly relevant
for hepatic I/R injury as the extent of succinate
accumulation was more pronounced in ischemic
livers (20-fold increase) than in other organs
(four-fold increase) [55
&&
]. Hypothermic oxygen-
ation before reperfusion appears as a novel treat-
ment to shift anaerobic metabolism to aerobic
metabolism under cold conditions, together with
huge ATP reload (Fig. 3). Whether citric acid meta-
bolite accumulation is reversed effectively by cold
oxygenated machine perfusion in human, remains
to be investigated.
Cellular defense effects
Hyperoxidation of respiratory chain proteins is
characteristic for mitochondria during reperfusion
after ischemia andmitochondrial dysfunction is the
primary site of ROS release leading to damage
[26,51]. However, not all ROS production is detri-
mental. Low levels of ROS are protective and may
serve as a trigger for activation of numerous path-
ways (PKCe, SIRT1, Nrf-2, and HIF-1) [57,58]. These
pathways increase the activation of antioxidant
enzymes (glutathione synthase, heme oxygenase,
catalase, glutathione, and manganese superoxide
dismutase), expression of angiogenic (erythropoe-
tin), and survival proteins (MAPK) [57]. Hypother-
mic machine perfusion may also exert upregulation
of defense pathways through minor ROS release
during cold perfusion, especially in livers exposed
to warm ischemia before perfusion (DCD grafts)
(Fig. 3). Further studies need to address this issue.
FUTURE APPLICATIONS
Based on the available data in human application
and on the proposed mechanism, the potential of
hypothermic machine liver perfusion appears
high. As it addresses ischemia reperfusion at its
roots, in contrast to traditional antioxidative thera-
pies, a number of novel strategiesmay be developed.
These include application of machine liver per-
fusion in steatotic livers to decrease oxidative
stress. Secondly, downstream effects of hypothermic
machine perfusion on immune response may be of
utmost importance in adapting immunosuppressive
therapy for transplanted tumor patients.
CONCLUSION
Safe use of liver grafts with significant hepatic
steatosis, or of livers exposed to long warm ischemia,
has been a major challenge in the era of high model
of end-stage liver disease recipients. Machine liver
perfusion offers a new strategy to optimize ex-vivo
organs before transplantation. Randomized trials
remain needed to identify the best liver perfusion
strategy, but endischemic HOPE is very effective. It is
currently the simplest machine perfusion approach,
with therefore high practicability and low-associated
costs. The full potential of this approach should be
discovered in the upcoming years.
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